A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Trial Profile

A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Alisertib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Ewing's sarcoma; Germ cell and embryonal neoplasms; Liver cancer; Neuroblastoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2016 Status changed from completed to active, no longer recruiting.
    • 13 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top